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Abstract
Background: Hepatocellular carcinoma (HCC) is characterized by late detection and fast progression, and it is believed that
epigenetic disruption may be the cause of its molecular and clinicopathological heterogeneity. A better understanding of
the global deregulation of methylation states and how they correlate with disease progression will aid in the design of
strategies for earlier detection and better therapeutic decisions.
Methods and Findings: We characterized the changes in promoter methylation in a series of 30 HCC tumors and their
respective surrounding tissue and identified methylation signatures associated with major risk factors and clinical correlates.
A wide panel of cancer-related gene promoters was analyzed using Illumina bead array technology, and CpG sites were
then selected according to their ability to classify clinicopathological parameters. An independent series of HCC tumors and
matched surrounding tissue was used for validation of the signatures. We were able to develop and validate a signature of
methylation in HCC. This signature distinguished HCC from surrounding tissue and from other tumor types, and was
independent of risk factors. However, aberrant methylation of an independent subset of promoters was associated with
tumor progression and etiological risk factors (HBV or HCV infection and alcohol consumption). Interestingly, distinct
methylation of an independent panel of gene promoters was strongly correlated with survival after cancer therapy.
Conclusion: Our study shows that HCC tumors exhibit specific DNA methylation signatures associated with major risk
factors and tumor progression stage, with potential clinical applications in diagnosis and prognosis.
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Introduction
Hepatocellular carcinoma (HCC) represents an endemic
burden worldwide, partially due to delayed diagnosis and
multiple risk factors that contribute to a permanent high
incidence [1,2]. Well-known risk factors include chronic
hepatitis B virus (HBV) and hepatitis C virus (HCV) infection,
toxic, metabolic and immune-related conditions [3]. In all these
conditions, the development of malignancy is the consequence
of a multistep process, including several morphologically
recognizable stages and usually associated with a context of
cirrhosis, a precancerous condition combining increased prolif-
eration and prolonged environmental stress. The sequential
progression to carcinoma has been related with changes at the
genetic and epigenetic level [4]. A number of previous studies
investigated genetic changes in HCC, including mutations and
deletions in candidate cancer-associated genes [4]. Somatic
mutations in several tumor suppressor genes (such as TP53, p16,
and RB), oncogenes (including c-MYC and b-catenin), and
other cancer-associated genes (including E-cadherin and cyclin
D1) have been observed in HCC. These changes have been
detected mainly in late stages of HCC development [4]. In
addition, a frequent identification of loss of heterozygosity
(LOH) in chromosome 8p in HCC cases, suggested that
inactivation of the Deleted in Liver Cancer 1 gene (DLC-1)
may play pivotal roles in HCC development [5]. However,
while genetic events are likely to contribute to the development
of HCC, neither of these genetic alterations has been
consistently identified in HCC, suggesting that epigenetic
changes may play an important role.
Aberrant DNA methylation is a major epigenetic mechanism
of gene silencing and is observed in many human cancers [6,7].
DNA methylation occurs in eukaryote DNA at CpG sites, usually
enriched in the promoters of genes. In several types of tumors,
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9749including HCC, global hypomethylation and specific promoter
hypermethylation have been linked with genomic instability and
inactivation of tumor suppressor genes (TSG), respectively [8,9].
Indeed, accumulating evidence indicates that HBV-infected
hepatocytes often exhibit altered epigenetic status [10,11]. In
this sense, a deregulated methylation profile can be an early
marker of disease and a useful tool for cancer screening. Several
studies support the potential role of promoter hypermethylation
in HCC-related gene silencing, and this has been shown to
be positively correlated with tumor progression [12]. Relevant
TSGs consistently found hypermethylated in HCC include
RASSF1A or p16INK4a [12,13,14,15,16,17,18]. However, al-
though a growing number of genes undergoing aberrant CpG
island hypermethylation in HCC has been described, most
studies have involved the analysis of hypermethylation in a
limited number of gene promoters or a restricted number of
HCC samples [12,13,14,15,16,17,18]. In addition to improving
our understanding of liver carcinogenesis, large scale DNA
promoter methylation profiles may produce useful associations
with clinical parameters such as recurrence and survival.
We studied a series of human HCC samples for DNA promoter
methylation using Illumina bead array analysis of 1505 CpG sites
in 807 cancer-related gene promoters. Signatures of a distinct
HCC methylation profile were obtained and validated, as well as
their potential application as clinical predictors.
Methods
Patients and Biopsy Specimens
All patients included in the study were referred for treatment to
Edouard Herriot Hospital in Lyon, France between 1997 and
2009. Tissue samples were used only from patients having signed
an informed-consent form; all tumor tissue samples were obtained
through the Tumorothe `que des Hospices Civils de Lyon. The
study was approved by the institutional review boards of the
International Agency for Research on Cancer and the local ethics
committee of Edouard Herriot Hospital.
38 patients with HCC were selected for analysis; in all cases,
cryopreserved samples from the primary tumor were available for
study; in 30 patients, paired cryopreserved samples of adjacent
non malignant tissue were also available (for clinicopathological
features, see Table 1). Samples from two patients with liver
adenoma were used for comparison purposes. An additional series
of 8 matched HCC and surrounding tissues was used for
validation. In addition, three different human HCC cell lines
(PLC/PRF/5, Hep3B, HepG2) and one breast carcinoma cell line
(MCF7) were included in the array.
For all patients, samples were taken from a surgical specimen,
obtained through hepatectomy or liver transplantation, under the
supervision of a pathologist; they were snap frozen less than 30
minutes after the removal of the surgical specimen and stored in
liquid nitrogen until use. Before molecular analysis, the represen-
tativity and the quality of the sample were verified by a pathologist
(Figure S1).
Information about risk factors for HCC was retrieved from
clinical charts; the following information was noted: serological
evidence for HBV or HCV infection, alcohol consumption,
evidence for dysmetabolic syndrome or auto-immune disease,
and other etiologies. Information about the evolution (treatments,
duration of follow-up, duration of survival, status at the date of last
information) was retrieved from clinical charts. The histological
diagnosis and classification of primary liver tumors and the
histological evaluation of the adjacent liver tissue were performed
by an experienced pathologist (JYS).
Bead array analysis of DNA promoter methylation
Tissues were frozen in liquid nitrogen, ground into powder and
then collected into eppendorf tubes. Genomic DNA from HCC
tumors and surrounding tissue was prepared by overnight
proteinase K treatment, phenol-chloroform extraction, and
ethanol precipitation. Sodium bisulfite modification was per-
formed on 500 ng DNA using the EZ DNA Methylation-Gold Kit
(Zymo Research). DNA methylation profiling using bead arrays
for 1505 CpG sites, corresponding to 807 cancer-related genes,
was performed with the Illumina GoldenGate methylation assay
(Illumina) as described previously [19]. Briefly, for each CpG site,
four probes are included: two allele-specific oligos (ASO) and two
locus-specific oligos (LSO). Each ASO–LSO oligo pair corre-
sponds to either the methylated or unmethylated state of the CpG
site. Each methylation data point is represented by two-color
fluorescent signals from the M (methylated) and U (unmethylated)
alleles. Technical replicates of several bisulfite-converted samples
were run. BeadStudio v3.2 software (Illumina) was used for initial
filtering and clustering analysis (see below).
Pyrosequencing
Genomic DNA from HCC tumors and surrounding tissue was
extracted and modified as described above. The eluted DNA was
at a final concentration of 25 ng/ml. To quantify the percentage of
Table 1. Clinicopathological features of HCC patients.
Variable No. of cases
No. of patients 30*
Male 24
Female 6
Age, mean 6 SD 59612.3
Etiology
HBV 9
HCV 5
Alcohol use 8
Unknown risk factor 8
Tumor differentiation
Well 15
Moderately 11
Poorly 4
Tumor size
,5c m 1 4
.5c m 1 6
TNM Stage
TI 14
TII 6
TIII 10
No. of nodules
Unilocular 14
Multilocular 16
Cirrhosis
Yes 16
No 14
*Only patients with paired samples (tumor and surrounding tissue) are
described here.
doi:10.1371/journal.pone.0009749.t001
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DNA was sequenced using a pyrosequencing system (PSQ
TM
96MA, Biotage, Sweden) [20]. This method treats each individual
CpG site as a C/T polymorphism and generates quantitative data
for the relative proportion of the methylated versus the
unmethylated allele. Pyrosequencing assays were established for
the quantitative measurement of DNA methylation levels in the
promoter region of 8 genes (RASSF1, GSTP1, APC, GNMT,
GABRA5, MEST, MGMT, and H19), and LINE-1 using primers
previously described [21]. (Table S1 and Figure S2). Hot-start PCR
was performed with HotStarTaq Master Mix kit (Qiagen), and
pyrosequencing was carried out in accordance with the manufac-
turer’s protocol (Biotage). The target CpGs were evaluated by
converting the resulting pyrograms into numerical values for peak
heights, and calculating the average of all CpG sites analyzed at a
given gene promoter (Figure S2).
Quantitative RT-PCR
Total RNA was isolated using the TRIzol Reagent (Invitrogen)
according to the manufacturer’s instructions. Reverse transcription
reactions were performed using MMLV-RT (Invitrogen) and
random hexamers, according to the manufacturer’s protocol.
Primers and probes were designed using Universal Probe Library
Assay Design Center (Roche). Quantitative real-time PCR (qRT-
PCR) was performed in triplicates of each condition, using
FastStart TaqMan Probe Master (Roche) and a MXP3000 real-
time PCR system (Stratagene).
Statistical Analysis
Filtering and unsupervised clustering. BeadStudio version
3.2 (Illumina) was used for obtaining the signal values (AVG-Beta)
corresponding to the ratio of the fluorescent signal from the
methylated allele (Cy5) to the sum of the fluorescents signals of
both methylated (Cy5) and unmethylated alleles (Cy3), 0
corresponding to completely unmethylated sites and 1 to completely
methylated sites. In order to avoid the gender effect, all probes in
chromosome X (n=84) were discarded. In addition, all probes with a
P value above 0.01 in more than 10% of the samples were excluded
from the analysis. BRBArrayTools software (version 3.8 beta2) was
used for further analysis, using the AVG-Beta values. CpG sites
showing minimal variation across the set of arrays were excluded
from the analysis. Gene ontology and molecular interactions were
analyzed with GenMAPP version 2.1 (http://GenMAPP.org/), and
the KEGG Pathways Database (http://www.genome.jp/kegg/).
Unsupervised hierarchical clustering, class comparison, class
prediction, KEGG pathway enrichment, and survival prediction
were performed with the BRBArrayTools software.
Class Comparison. CpG sites were considered differentially
methylated when their P value was less than 0.001. In addition, we
identified CpG sites that were differentially methylated between
tumor and adjacent tissue by using a multivariate permutation test
[22] providing 90% confidence that the false discovery rate was
less than 10%. The false discovery rate is the proportion of the list
of CpG sites claimed to be differentially methylated that are false
positives. The test statistics used are random variance t-statistics
for each CpG site [23]. Although t-statistics were used, the
multivariate permutation test is non-parametric and does not
require the assumption of Gaussian distributions. A global test of
whether the methylation profiles differed between the classes was
also performed by permuting the labels of which CpG methylation
states corresponded to which classes. For each permutation, the P
values were re-computed, and the number of CpG sites significant
at the 0.001 level was noted. The proportion of the permutations
that gave at least as many significant CpG sites as with the actual
data was the significance level of the global test (P,0.05 for the
global test).
In addition, we performed an alternative analysis consider-
ing the frequency of methylation in tumors respective to
surrounding tissue. To this end, we defined a threshold for
frequently unmethylated and frequently methylated genes
based on the 25 and 75 percentiles in the surrounding tissues,
respectively. This is, a given CpG site was considered as
frequently hypermethylated in tumors if more than 75% of the
tumor samples lied above the 75 percentile in surrounding
tissues. Similarly, if more than 75% of the tumor samples lied
below the 25% of methylation in surrounding samples, this
CpG site was considered as frequently hypomethylated in
tumors (Figure S3).
Class Prediction. We used different models to predict the
class of future samples using CpG methylation profile based on
the Compound Covariate Predictor [24], Diagonal Linear
Discriminant Analysis [25], Nearest Neighbor Classification
[25], and Support Vector Machines with linear kernel [26].
The models incorporated CpG sites that were differentially
methylated at the 0.001 significance level as assessed by the
random variance t-test [23]. We estimated the prediction error of
each model using leave-one-out cross-validation (LOOCV) [27].
For each LOOCV training set, the entire model building process
was repeated, including the gene selection process. We also
evaluated whether the cross-validated error rate estimate for a
model was significantly less than one would expect from random
prediction. The class labels were randomly permuted and the
entire LOOCV process was repeated. The significance level is the
proportion of the random permutations that gave a cross-
validated error rate no greater than the cross-validated error rate
obtained with the real data. 1000 random permutations were
used.
In addition, the Prediction Analysis for Microarrays (PAM)
T o o lw a su s e da sa n o t h e rm e t h od of class prediction. The
method uses the shrunken centroid algorithm [28], whereby the
c e n t r o i d so fe a c hg r o u pa r es h r u n k e nt o w a r de a c ho t h e rb y
shrinking the class means of each CpG site toward an overall
mean. The amount of shrinking is determined by a ‘‘tuning
parameter’’ called delta. As the shrinking occurs, some CpG
sites will have the same value of shrunken class mean for the
different classes, and hence they will have no effect in
distinguishing the classes. For larger values of delta, fewer
CpG sites will have different shrunken means among the classes,
and so the classifier will be based on fewer CpG sites. With this
approach, the number of CpG sites included in the classifier is
determined by the value of delta. The algorithm provides a k-
fold cross-validated estimate of prediction error for all values of
delta where k is the minimum class size. The tool indicates the
delta corresponding to the smallest cross-validated prediction
error and gives the list of CpG sites that are included in the
classifier for that value of delta.
Gene Ontology Analysis. The evaluation of which Gene
Ontology (GO) classes are differentially methylated between
tumor and surrounding samples was performed using a
functional class scoring analysis as previously described [29]. For
each gene in a GO class, the P value for comparing tumor and
surrounding samples was computed. The set of P values for a class
was summarized by two summary statistics: (i) The LS summary is
the average log P values for the genes in that class and (ii) the KS
summary is the Kolmogorov-Smirnov statistic computed on the P
values for the genes in that class. Functional class scoring is a more
powerful method of identifying differentially methylated gene
classes than the more common over-representation analysis or
Methylome Signature in HCC
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functional class scoring analysis for GO classes was performed
using BRB-ArrayTools.
Survival Analysis. CpG sites whose methylation was
significantly related to overall survival after treatment were
selected with BRB-ArrayTools survival analysis. A statistical
significant level was computed for each gene based on univariate
proportional hazards models. These P values were then used in a
multivariate permutation test in which the survival times and
censoring indicators were randomly permuted among arrays
[27,30]. The multivariate permutation test was used to provide
90% confidence that the false discovery rate was less than 10%.
For other comparisons, means and differences of the means
with 95% confidence intervals were obtained using GraphPad
Prism (GraphPad Software Inc.). The Mann-Whitney test and
the Wilcoxon matched pairs test were used for unpaired and
paired analysis comparing average methylation between classes,
respectively. P values,0.05 were considered statistically
significant.
Results
DNA promoter methylation in HCC samples
To investigate whether HCC could harbor specific methylation
profiles, DNA methylation of 1505 CpG sites was analyzed using
Illumina bead arrays. A total of 38 HCC samples were suitable
for analysis, including 30 pairs of HCC tumors/surrounding
tissues. In addition, 4 liver adenoma tumors/surrounding samples
and 4 cancer cell lines were included for comparison. 1219
Probes were used in the analysis, after excluding those with a P
value higher than 0.01 in more than 10% of the samples, and
those in chromosome X (to avoid the gender effect). An initial
unsupervised hierarchical clustering analysis was able to distin-
guish HCC samples from other types of tumors (breast and
esophageal cancer), blood and cell lines (data not shown).
Unsupervised clustering within HCC samples was also able to
distinguish 2 clusters enriched in tumors and surrounding tissue
samples (Figure 1A). Together with the proper clustering of the
replicates in the unsupervised analysis, the scatter plots analysis
confirmed the quality and reproducibility of the methylation
profiling (Figure 1B).
Overall, tumor samples displayed a small but significant increase
in average promoter CpG methylation (median methylation of 0.16
and 0.23 for surrounding and tumor tissue, respectively, P,0.05)
(Figure 1C). This contrasts with the global DNA methylation as
assessed with the LINE-1 element [21], which shows a significant
hypomethylation in tumors compared to surrounding tissue
(P,0.005, Figure S2C). An unsupervised analysis of samples
grouped by risk factors (HBV, HCV, alcohol consumption, or
unknown risk) showed that surrounding tissues were clustered
together, while tumor tissues were in a separate group among
which HCV-associated HCC were the most divergent subset
(Figure 1D). When analyzing the average promoter methylation for
these groups, an increased methylation was consistently found in
tumor samples relative to surrounding tissue, with the exception of
adenoma samples (Figure 1E). This increase in average promoter
methylation was statistically significant for HBV and HCV samples
(P,0.0001 for both paired analysis). Although promoter methyl-
ation was also increased in alcohol-related and unknown-risk HCC
samples, the difference did not reach statistical significance.
Therefore, a distinct promoter methylation profile is common to
all HCC tumors, with global non-promoter hypomethylation and
increased promoter methylation.
Signature and prediction of HCC by DNA promoter
methylation profiling
To distinguish those genes differentially methylated between
tumors and surrounding tissue, a class comparison tool (BRBAr-
rayTools v3.8) was used, as described in Methods. After filtering
for a P value,0.001 and correcting for a False Discovery Rate
(FDR) ,0.1, 124 CpG sites were shown to be differentially
methylated. Several CpG sites corresponded to the same gene
promoter, and consequently a total of 94 genes were considered as
differentially methylated. Approximately one third of the signif-
icant promoters were significantly represented by more than one
CpG site, arguing in favor of the quality of this data. Relative to
surrounding tissues, tumors showed increased methylation in 34
(27%) of these CpG sites (corresponding to 27 gene promoters,
including RASSF1, APC, and CDKN2A), and reduced methylation
in 90 (73%) (corresponding to 66 gene promoters, including
GABRA5, NOTCH4, and PGR) (Figure 2A and Table S2). To
analyze the frequency of methylated or unmethylated CpG sites in
tumors relative to surrounding tissue we used the upper and
lower quartile of surrounding tissue to set a threshold (see
Methods). This analysis yielded a similar result, with 7 and 35 CpG
sites respectively hyper- and hypomethylated in tumors (Figure S3).
Validation of a subset of 8 gene promoters by pyrosequencing
was consistent with the bead arrays results (Figure S4A). The
correlation between pyrosequencing and bead array analysis was
statistically significant (P value,0.0001, Figure S4B). In addition,
hypermethylation of RASSF1A and of APC promoters was
associated with a significantly lower expression in HCC tumors,
as assessed by qRT-PCR (Figure S5).
The ontological analysis of the differentially methylated genes
showed enrichment for ontology terms related to development,
including the Wnt-b2catenin, TGF-b, Hedgehog and Notch
signaling pathways (data not shown). Methylation of some of these
genes has been previously described in HCC (i.e. APC, RASSF1A,
and p16/CDKN2A), validating the sensitivity of this assay
[14,31,32]. However, many gene promoters that were not
previously linked to HCC showed differential methylation,
including those involved in apoptosis (IRAK3, MYOD1), immune
response (HLA-DQA2, GSTM2, IFNG), growth factor signaling
(EGF, FGF6, IGF1R, NGFR), cell cycle regulation (CCND2), and
metastasis (CDH17, MMP1, MMP3, MMP9) (Table S2). Interest-
ingly, promoters in the HCC signature included a number of
imprinted genes that were consistently hypomethylated in HCC
relative to surrounding tissue (GABRA5, GABRG3, HBII-52,
MEST, MKRN3, TRPM5, and ZIM3). For most of them there
were at least 2 CpG sites differentially methylated, suggesting that
this observation is biologically significant.
Figure 1. Unsupervised analysis of CpG methylation bead arrays in HCC. A. Clustering analysis of 76 HCC samples included in the bead
array assay (HCC tumor and surrounding tissue). For the upper part of the cluster, names are given manually according to the enrichment of specific
clusters. 1505 CpG sites are included. Yellow indicates hypomethylated, and red hypermethylated CpG sites. B. Representative logarithmic plot of
two replicates included in the array, showing proper consistency of methylation (r2 value is included on the plot). C. Average promoter methylation
of all 1505 CpG sites, in HCCs and surrounding tissues. D. Clustering analysis after grouping the samples by ethological factors. E. Average
methylation for all 1505 CpG sites from the same ethological groups shown in (d). Significant differences (P,0.05) between tumor and surrounding
tissue are represented with an asterisk (*).
doi:10.1371/journal.pone.0009749.g001
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have clinical impact, especially when small sets of genes are able to
produce robust predictions. The significant differences between
surrounding and HCC tissues after class comparison suggested the
possibility of building a multivariate predictor from this gene set.
Therefore, we next used a subset of CpG sites to predict the class
of an independent series of HCC tumors and matching
surrounding tissues. The models incorporated genes that were
differentially methylated between tumor and surrounding tissue at
the 0.001 significance level, as assessed by the random variance t-
test. The prediction error of each model was assessed using leave-
one-out cross-validation (LOOCV) [27]. Interestingly, the 124
CpG sites included in the HCC signature were able to
discriminate tumor and surrounding tissue in all the samples
included in the second series (data not shown).
We next tried to design a predictor with a minimum number of
CpG sites using the Prediction Analysis of Microarrays tool (PAM)
[28]. As shown in Figure 2B, a minimum of 20 CpG sites is
required to minimize the number of misclassification errors. This
20 CpG site predictor (corresponding to 16 gene promoters) was
able to correctly classify 14 out of 16 of the new samples
(sensitivity=0.75, specificity=0.97 for tumor prediction), and was
included in the 124 CpG sites signature of HCC. An unsupervised
clustering for the new series of HCC samples using this 20 CpG
sites-signature highlights its ability to discriminate both types of
samples (Figure 2C). Interestingly, the CpG sites with strongest
ability to discriminate tumor from surrounding tissue were found
in the promoter of genes hypermethylated in HCC samples (e.g.
APC, RASSF1A, CDKN2A, and FZD7).
Methylation profile is associated with HCC risk factor and
tumor progression
In order to find CpG sites potentially associated with tumor
progression, we performed a class comparison analysis to classify the
methylation profile according to tumor stage (as assigned by the
TNM classification) and grade of differentiation (histologically
classified as 1 = well differentiated, 2= intermediate, and 3=
poorly differentiated). Tumor stage will be referred to as T, as all
samples except one [T3N1M0] sample were negative for lymph
node invasion (N0) and metastasis (M0). Globally, tumors of the first
2 stages (T1 and T2) displayed a similar methylome profile, while 24
CpG sites were differentially methylated in advanced tumors (T3)
(Figure 3A). All CpG sites were significantly hypermethylated in
advanced tumors, and most of them show a trend to be progressively
hypermethylated from T1 through T3 (Figure 3A). The set of 24
CpG sites hypermethylated in advanced HCC tumors are located in
genes involved in immune response and adhesion (IL18BP, IPF1,
HLA-DOB, CSPG2, GJB2 and PMP22), and the cell cycle (CCND2
and NTKR3). Similarly, the grade of differentiation was associated
with changes in methylation only in the least differentiated tumors
(grade 3) (data not shown). Three CpG sites were significantly
hypomethylated in grade 3 tumors (e.g. HOXB2, DDR2,a n d
TIMP3), while 19 CpG sites were hypermethylated (including CDK2,
EF3, FANCF, LIF, RASGRF1, DNMT1,a n dERCC1).
The HCC samples analyzed in this study were obtained from
patients exposed to different risk factors, including HBV infection,
HCV infection, and ethanol consumption. In order to identify risk
factor-specific profiles of methylation we performed a class
comparison analysis including these groups, and a group of
HCC samples with unknown risk factors (negative for HBV or
HCV infection, and no history of alcohol consumption). After class
comparison analysis, a reduced set of genes was significantly
hypermethylated in each group relative to the other 3 groups
(Figure 3B). By comparing among these groups it was possible to
select CpG sites specifically modulated in alcohol-related (DIO3
and STAT5A), HBV-related (NAT2, CSPG2, DCC, NTKR3,
TNFSF10, TNFRSF10C, and RASGRF1), and HCV-related HCCs
(RIK and CHGA). Samples from unknown risk factor patients
displayed a mixed profile, with hypermethylation of several of
these promoters, probably reflecting their heterogeneous origin
(Figure 3 and Table S3).
The heterogeneity of HCC origin is also reflected in the
conservation of the normal architecture of the liver. In this sense,
our series of HCC surrounding tissues can be classified into those
samples exhibiting cirrhotic (n=16) or non-cirrhotic (n=14)
histology. Comparison between these two classes using stringent
conditions of analysis (P value,0.001) shows that cirrhotic tissues
are significantly hypermethylated in 2 gene promoters, corre-
sponding to UGT1A7 and PLG.
HCC methylation profile and prediction of survival
Survival signatures were developed with BRB-ArrayTools using
fitted Cox proportional hazards model, considering the time of
biopsy as the starting point. At the time of analysis there were 13
deaths among 38 patients with available data, with a mean follow-
up time of 194 weeks for all patients. With these data it was
possible to classify the patients into two groups with significantly
different survival curves (Figure 4A, P,0.001). The first 10 CpG
sites with highest ability to differentiate between these two groups
are shown in Figure 4B. Interestingly, this survival signature was
significantly enriched in the promoters of genes involved in IGF-1
signaling and immune response (Figure 4C). In addition, the
differences found in DNA promoter methylation were reflected in
different expression profiles for some of the genes ranking highest
in the survival prediction analysis (Figure 4D). This suggests that
control of immune and growth factor response genes by
methylation may represent a potential mechanism directly
affecting the survival of HCC patients.
Discussion
This report describes the CpG methylation profile of HCC in a
wide panel of cancer-related promoters. A differential analysis
identified a signature of the genes specifically methylated in HCC
with respect to surrounding tissue. Although a number of known
promoters were found to be differentially methylated in HCC, we
identified new candidate promoters that are potentially involved in
the development and progression of liver cancer. By correlating
the methylation data with clinical outcomes it was possible to
Figure 2. Signature and predictor of HCC by methylation profiling. A. Differential methylation analysis was performed with the class
comparison tool of BRBArrayTools software, as described in Materials and Methods. The heat map represents those CpG sites distinguishing HCC
from surrounding tissue (n=87) with a P value,0.001. The full list of CpG sites is presented as Table S2. Yellow indicates hypomethylated, and red
hypermethylated CpG sites. B. Representation of the misclassification error as a function of the number of genes, as assessed with the PAM
prediction analysis. The upper panel shows the correlation for the grouped samples; the lower panel shows the independent correlation for tumor
and surrounding samples. Sensitivity and specificity of the predictor is included in the Figure. C. A heat map with the 20 CpG sites included in the
HCC predictor was obtained for an independent series of HCC samples and HCC surrounding tissues, after unsupervised hierarchical clustering
analysis.
doi:10.1371/journal.pone.0009749.g002
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PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9749Figure 3. Methylation profile according to risk factor and tumor progression. Class comparison analyses were performed, as described in
Figure 2. A. The heat map represents 27 CpG sites distinguishing the different HCC samples according to their TNM classification, with a P
value,0.05. B. The heat map represents 17 CpG sites distinguishing the different HCC samples according to their ethological exposure, with a P
value,0.01. HBV or HCV infection, EtOH = ethanol consumption, and Unknown = unknown risk factor.
doi:10.1371/journal.pone.0009749.g003
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clinical parameters such as stage and grade. The strength and low
complexity of these signatures, based on a reduced number of gene
promoters, makes them a potential novel strategy for early
detection and clinical prediction in HCC.
Although early detection of HCC has improved, diagnosis is
established at only advanced stages. Therefore, there is an urgent
need to predict recurrence and response to therapy, especially
because patients prone to recurrence may receive alternative
treatment. The strength of the presented signatures is underscored
by their validation in an independent series of HCC samples.
Importantly, despite preliminary studies on clinical prediction
based on gene expression profiling [33], the stability of DNA
relative to RNA makes methylation profiling a tool better suited to
clinical settings. In addition, the availability of signatures with a
reduced number of CpG sites would enable their use for clinical
prediction in, for example, paraffin-embedded samples or plasma
DNA. A small set multivariate predictor may have important
applications in the early detection of neoplastic transformation in
populations at high risk for HCC, such as hereditary haemochro-
matosis patients [18]. Similarly, the prediction of survival may be
useful in improving and individualizing therapeutic decisions.
However, these multivariate signatures should be prospectively
validated in larger cohorts before considering clinical applications.
The importance of the role of DNA methylation has been
previously described in HCC. Epigenetic changes on RASSF1A,
p16, and p15 tumor suppressor genes in serum DNA have been
shown to be potential biomarkers for early detection in
populations at high risk for HCC [18]. The tumor suppressor
APC also seems to be a common marker for HCC detection and is
found consistently hypermethylated in HCC [12], whereas SYK
and CRABP1 hypermethylation has been considered as a useful
prognostic marker in HCC [34]. A previous screening of 105
promoters identified that the epigenetic activation of Ras and
downstream Ras effectors was common in HCC, and was
associated with poor prognosis [8]. In another study, increased
methylation was shown in the p16 and GSTP1 genes in HCC
compared to matching non-malignant cirrhotic liver [12,35,36]. In
this sense, our bead array analysis supports and extends the
previous findings on DNA methylation, and provides a novel and
more comprehensive signature of HCC methylation.
A previous study analyzed a limited panel of cancer-associated
genes in HCC tumors and found that environmental factors may
influence the degree and pattern of methylation in tumors [37].
Our study identified significant associations between methylation
patterns and specific etiologic agents (i.e., HBV, HCV, and
ethanol), tumor progression (stage and grade of differentiation),
and tumor background (cirrhotic vs. non-cirrhotic surrounding
tissue) for specific subsets of genes. Interestingly, those promoters
differentially methylated in virus-related HCC samples correspond
to genes involved in immune response and induction of apoptosis.
Specifically, polymorphisms of the N-acetyltransferase encoded by
the NAT2 gene have been linked to susceptibility to HBV-related
HCC [38,39]. Moreover, promoter methylation of DNMT1 was
associated with poor differentiation.. Remarkably, hypermethyla-
tion of the gene encoding DNA-methyltransferase 1 (DNMT1) can
be associated with a lower expression and consequent global
hypomethylation as observed with the LINE-1 pyrosequencing
analysis.
Another interesting observation is that the tumor background
(cirrhotic vs. non-cirrhotic) determined a specific pattern of
methylation for several promoters. UGT1A7 encodes a UDP-
glucuronosyltransferase involved in multiple metabolic pathways,
including the metabolism of hormones and the metabolism of
xenobiotics by cytochrome P450. In addition, UGT1A7 polymor-
phisms have been correlated with cirrhosis, and with increased risk
of HCC in HBV- and HCV-infected patients [40,41,42]. Similarly
plasminogen, encoded by PLG, is a circulating zymogen that is
converted to the active enzyme plasmin and whose main function
is to dissolve fibrin clots. It is noteworthy that PLG transcript
expression has been reported to be reduced in HCC [43].
Therefore, aberrant promoter methylation of these two genes may
be related with a disturbed detoxification of carcinogens, and the
process of hepatic fibrogenesis that results in cirrhosis [44]. Further
analysis of these genes may shed new light into the process of liver
carcinogenesis in specific risk groups. However, the global
similarity among HCC groups substantiates the notion that
aberrant methylation is a ubiquitous phenomenon in liver
carcinogenesis [8].
In summary, this study describes the methylation profile of
hepatocellular carcinoma and the specific signatures that can be
used as markers for detection and survival after therapy. Our
results, based on bead arrays and quantitative analysis with
pyrosequencing, give a reliable view of HCC promoter methyl-
ation in a wide panel of genes, and can be used as a reference tool
for the potential development of clinical applications.
Supporting Information
Figure S1 Representative histology of HCC tumors and
surrounding tissues used for methylation profiling. H&E-stained
HCC samples with surrounding non-tumor liver parenchyma.
Examples of HCC samples with adjacent non-cirrhotic and
cirrhotic tissues are shown in A and B, respectively. NC indicates
non-cirrhotic surrounding liver tissue, C indicates cirrhotic
surrounding liver tissue, and H indicates HCC tissue.
Found at: doi:10.1371/journal.pone.0009749.s001 (7.59 MB TIF)
Figure S2 Pyrosequencing design for imprinted genes. A.
Diagram showing chromosomal localization and GC percentage
for GABRA5 promoter, as an example of the design used for
validation. The regions studied by bead arrays and pyrosequen-
cing are represented under the chromosomal localization. B.
Representative pyrograms of GABRA5 obtained from the analysis
of bisulfite-modified DNA from HCC tumor and surrounding
tissue. Primers used for pyrosequencing are included as Supple-
mentary Table 1. C. Global methylation was studied using primers
against LINE-1 elements [21]. A significant hypomethylation in
tumors, relative to surrounding tissue, is shown by a (*) (,0.05).
Found at: doi:10.1371/journal.pone.0009749.s002 (1.54 MB TIF)
Figure S3 Analysis of frequency of methylation. AVG-Beta
values in the surrounding tissues were used to define the
percentiles 25 and 75 for each CpG site (see Methods). These
Figure 4. Survival risk predictor in HCC. A. Survival analysis using BRB-ArrayTools. A survival signature was developed using fitted Cox
proportional-hazards model and leave-one-out crossvalidation, considering the time of biopsy as the starting point. Survival curves show a significant
difference between two groups of HCC patients. B. A 58 CpG sites predictor (selected from the analysis shown in A.) was correlated with survival
after treatment. Only the first 10 CpG sites (with the lowest P value) are shown. C. Pathway analysis for the 58 CpG sites included in the survival
predictor showing the 5 significantly enriched pathways. D. Quantitative RT-PCR was performed for some of the genes with the highest ability to
predict survival in HCC (MYLK, FLT1, CDKN1C and TAp73, in a subset of samples with high (H) and low (L) risk.
doi:10.1371/journal.pone.0009749.g004
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methylation in tumors. A. Box plots representing the 3 CpG sites
with highest frequency of methylation in tumors (upper panel) and
highest frequency of unmethylation in tumors (lower panel)
calculated in this way. S = surrounding, T = tumor. (*) P value
, 0.001. B. Table showing the CpG sites frequently methylated in
more than 75% of the tumors relative to surrounding tissues. C.
Table showing the CpG sites frequently unmethylated in more
than 75% of the tumors relative to surrounding tissues.
Found at: doi:10.1371/journal.pone.0009749.s003 (2.56 MB
TIF)
Figure S4 Validation of bead arrays by pyrosequencing A.
Pyrosequencing assays were designed for the validation of 8 gene
promoters differentially methylated between tumor and surround-
ing HCC samples (upper dot plot). The level of methylation is
shown in a percentage scale. Primers were designed as described in
Materials and Methods. A dot plot representing the corresponding
levels of methylation (in a 0 to 1 scale) for the same genes in the
bead arrays assay is shown in the lower panel. B. Correlation
analysis from the data presented in (A).
Found at: doi:10.1371/journal.pone.0009749.s004 (1.45 MB TIF)
Figure S5 Validation of bead arrays by qRT-PCR Quantitative
RT-PCR was performed for APC and RASSF1A in a subset of
samples. The bars show a lower expression in the tumors relative
to surrounding tissue in 3 out of 4 samples analyzed. In addition,
inverse correlation with methylation is shown in each plot. Each
line represents the AVG-Beta value obtained with bead arrays for
2 independent probes in the same promoter. Higher initial
methylation is observed for the last sample, in which expression in
tumors is higher than the matched surrounding tissue.
Found at: doi:10.1371/journal.pone.0009749.s005 (2.17 MB TIF)
Table S1 Primers used for pyrosequencing.
Found at: doi:10.1371/journal.pone.0009749.s006 (0.06 MB
DOC)
Table S2 CpG sites differentially methylated in HCC tumor vs.
surrounding tissue.
Found at: doi:10.1371/journal.pone.0009749.s007 (0.25 MB
DOC)
Table S3 CpG sites differentially methylated in HCC according
to risk factor exposure.
Found at: doi:10.1371/journal.pone.0009749.s008 (0.07 MB
DOC)
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